

Antigen level signals response to chemo for pancreatic cancer

17 August 2015



Illustration: U.S. Department of Health and Human Services

related [to] better survival outcomes in unresectable PDAC," the authors write.

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2015 [HealthDay](#). All rights reserved.

(HealthDay)—A drop in carbohydrate antigen (CA) 19-9 levels of more than 10 percent after two rounds of chemotherapy is associated with longer survival in patients with advanced pancreatic ductal adenocarcinoma (PDAC), according to a study published online Aug. 6 in the *Journal of Gastroenterology and Hepatology*.

Kwang Hyun Chung, from Seoul National University College of Medicine in South Korea, and colleagues assessed the correlation between early decrement in CA 19-9 concentration and prognosis of advanced PDAC (183 patients) after at least two rounds of [chemotherapy](#) (between January 2012 and December 2013). Serum CA 19-9 concentrations were measured at baseline and eight weeks after the initiation of chemotherapy.

The researchers found that overall survival (OS) and time to progression (TTP) were significantly longer for patients whose serum CA 19-9 concentration decreased more than 10 percent from baseline (103 patients) versus patients whose serum CA 19-9 did not decrease (80 [patients](#); P

"The early decrement of CA 19-9 after the initiation of chemotherapy was an independent factor

APA citation: Antigen level signals response to chemo for pancreatic cancer (2015, August 17) retrieved 18 September 2020 from <https://medicalxpress.com/news/2015-08-antigen-response-chemo-pancreatic-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.